Professor G Kees Hovingh
Disclosure details
G.K.H. reports research grants from the Netherlands Organization for Scientific Research (vidi 016.156.445), CardioVascular Research Initiative, European Union and the Klinkerpad fonds, institutional research support from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Ionis, Kowa, Pfizer, Regeneron, Roche, Sanofi, and The Medicines Company; speaker’s bureau and consulting fees from Amgen, Aegerion, Sanofi, and Regeneron until april 2019 (fees paid to the academic institution); and part-time employment at Novo Nordisk A/S, Denmark since April 2019.Staff Member and Head of Clinical Trial Unit, Academic Medical Center, Amsterdam, The Netherlands
